Clinical trial
Phase II Randomized, Double-Blind, Placebo-Controlled Study of BMS-188667…
NCT00287547 · Bristol-Myers Squibb, Industry · Completed
Key facts
| NCT number | NCT00287547 |
|---|---|
| Title | Phase II Randomized, Double-Blind, Placebo-Controlled Study of BMS-188667 (CTLA4Ig) in Patients With Psoriasis Vulgaris |
| Official title | Phase II Randomized, Double-Blind, Placebo-Controlled Study of BMS-188667 (CTLA4Ig) in Patients With Psoriasis Vulgaris |
| Lead sponsor | Bristol-Myers Squibb, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Psoriasis Vulgaris |
| Intervention type | Drug |
| Interventions | CTLA4Ig / Abatacept |
| Enrollment | 144 |
| Start date | Mar 1, 1997 |
| Primary completion | Jan 1, 1998 |
| Completion | Jan 1, 1998 |
| First posted | Feb 7, 2006 |
| Last update posted | Apr 25, 2011 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: